Aldevron Revenue and Competitors

Fargo, ND USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Aldevron's estimated annual revenue is currently $15.8M per year.(i)
  • Aldevron received $Undisclosed in venture funding in January 2017.
  • Aldevron's estimated revenue per employee is $155,000

Employee Data

  • Aldevron has 102 Employees.(i)
  • Aldevron grew their employee count by -89% last year.

Aldevron's People

NameTitleEmail/Phone
1
Chief IP CounselReveal Email/Phone
2
Executive Assistant to President & CFOReveal Email/Phone
3
Chief Financial OfficerReveal Email/Phone
4
VP ManufacturingReveal Email/Phone
5
VP/GM mRNA ServicesReveal Email/Phone
6
VP, Program ManagementReveal Email/Phone
7
VP, Information Technology and SecurityReveal Email/Phone
8
EVP Human ResourcesReveal Email/Phone
9
VP, Client Services, DNAReveal Email/Phone
10
VP, Global Technical OperationsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$2.6M170%N/AN/A
#2
$1M138%N/AN/A
#3
$2.3M15-12%N/AN/A
#4
$15.8M102-89%N/AN/A
#5
$0.8M50%N/AN/A
#6
$4.8M31-3%N/AN/A
Add Company

What Is Aldevron?

Aldevron provides contract manufacturing and scientific services. We specialize in plasmid DNA, protein production, and antibody generation. PLASMID DNA PRODUCTION With the successful completion of over 50,000 projects, we have developed unsurpassed expertise in plasmid manufacturing. Using proprietary technology, Aldevron manufactures DNA for a wide range of research, preclinical, clinical, and diagnostic applications (1 mg to 100 g). PROTEIN PRODUCTION Aldevron offers a wide range of protein services including host cell optimization, expression screening, process development, contract production, enzyme and antibody assay design, and more. Proteins produced by Aldevron are used for a wide range of agriculture and biomedical applications from research grade to full cGMP. ANTIBODY GENERATION GENOVAC Antibody Technology supports all project types from reagent antibodies to diagnostic and therapeutic applications with high success rates. Based on many years of experience, our immunization technology has been developed to cater for all protein targets where other methods have failed (including e.g. GPCRs). Our custom antibodies have been validated in over 130 publications and patents for more than 500 clients worldwide. Additional services include antibody processing, production, labeling, characterization and sequencing.

keywords:Biotechnology,Healthcare,Pharmaceuticals

N/A

Total Funding

102

Number of Employees

$15.8M

Revenue (est)

-89%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Aldevron News

2022-04-19 - Global GMP Grade Plasmid DNA Market Competitive Analysis ...

Aldevron; Kaneka Eurogentec; Cobra Biologics; VGXI; AGC Biologics; Waisman Biomanufacturing; PlasmidFactory; Nature Technology Corporation (NTC)...

2022-04-17 - Global GMP Plasmid DNA Market 2022 Industry Demand, Top ...

Aldevron; Kaneka Eurogentec; Cobra Biologics; VGXI; AGC Biologics; Waisman Biomanufacturing; PlasmidFactory; Nature Technology Corporation (NTC)...

2022-03-30 - Large Market Deal of the Year: EQT and Aldevron

Headquartered in Fargo, North Dakota, Aldevron manufactures plasmid DNA, which is a material needed to synthesize mRNA therapies and vaccines,...

2021-04-29 - ZIOPHARM ONCOLOGY, INC. Aldevron Announces Virtual Breakthrough Speaker Series: Dr. Laurence Cooper is Inaugural Guest

Aldevron hosted its first Breakthrough Symposium (BTS) in Fall 2018 with an exciting lineup of industry leaders presenting their research and how it affects the present, and the future, of finding solutions to the world's biggest health challenges. Our inaugural presentation for the Breakthroug ...

2019-09-02 - Global Viral Vectors and Plasmid DNA Manufacturing Market ...

Major Participants of worldwide Global Viral Vectors and Plasmid DNA Manufacturing Market: Aldevron, Eurogentec, Richter-Helm, ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$14.9M1035%N/A
#2
$15.1M104-5%N/A
#3
$26.3M1074%N/A
#4
$10.8M1084%N/A
#5
$7.5M108-1%N/A

Aldevron Funding

DateAmountRoundLead InvestorsReference
2017-01-25$UndisclosedUndisclosedTA AssociatesArticle